Brands
Mankind Pharma Q3 FY26 revenue rises 11.5 per cent
MUMBAI: It appears that Mankind Pharma has found the perfect prescription for growth, proving that even in a volatile market, they have the right chemistry to stay ahead. While others might be feeling a bit under the weather, the Delhi-based drugmaker reported a robust 11.5 per cent year-on-year increase in revenue, reaching a healthy Rs 3,567 crore for the third quarter of FY26. It seems that for Mankind, the best way to treat a financial fever is with a steady dose of chronic care and a strategic dash of super-specialty acquisitions.
The domestic market remains the company’s strongest vital sign, contributing a massive 85 per cent of total revenue. Domestic operations brought in Rs 3,046 crore, up 11.1 per cent from the previous year. This growth was largely fuelled by the company’s increasing focus on “chronic” therapies, those long-term medications for conditions like heart disease and diabetes, which now make up 39.3 per cent of their domestic share.
Specifically, the cardiac segment jumped by 16.7 per cent, while anti-diabetes treatments grew by 14.4 per cent. Key brands like the Telmikind family (up ~21 per cent) and Glizid (which crossed the Rs 200 crore mark) are doing the heavy lifting. Even the Consumer Healthcare wing, home to household names like Manforce and Prega News, regained its pulse with a 5.2 per cent growth, reaching Rs 203 crore after a slightly sluggish second quarter.
Mankind isn’t just sticking to the basics; its recent acquisition of BSV (Bharat Serums and Vaccines) is already adding some serious muscle to the portfolio. BSV’s specialty complex products, which deal with high-entry-barrier areas like fertility and critical care, saw strong double-digit growth this quarter.
On the global front, the company’s export business is looking positively radiant. Revenue from international markets climbed 14.1 per cent to Rs 521 crore. In the US alone, Mankind has now launched 48 products, with four new additions in the first nine months of the financial year.
. Ebitda: Reported at Rs 816 crore, though when adjusted for one-time costs like labour code regulations, the “Adjusted EBITDA” stands at a sturdier Rs 923 crore with a margin of 25.9 per cent.
. Profit after tax (PAT): Came in at Rs 414 crore, a 9.5 per cent increase YoY.
. Cash flow: The company maintains a high-octane cash conversion, with Cash Flow from Operations at Rs 2,398 crore for the first nine months of FY26.
. Market standing: Mankind remains the #2 player in the Indian Pharmaceutical Market (IPM) by volume and holds the #1 spot for prescriptions, covering over 5 lakh doctors with a field force of 18,000.
Vice chairman & managing director Rajeev Juneja noted that the company remains “confident of delivering long-term sustainable growth,” anchored by the “four key pillars” of their base business, specialty chronic segments, OTC brands, and the new BSV super-specialty portfolio. With 23 brand families now worth over Rs 100 crore each, Mankind Pharma seems to have found a recovery plan that is both painless and profitable.